Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 22, Issue 3, 1998, Pages 241-244

  Schuler, U S ^a   Ehrsam, M ^a   Schneider, A ^a   Schmidt, H ^a   Deeg, J ^b   Ehninger, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bioavailability; Busulfan; Dimethylsulphoxide; Pharmacokinetics

Indexed keywords

BUSULFAN; DIMETHYL SULFOXIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG FORMULATION; DRUG INFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POWDER; PRIORITY JOURNAL;

EID: 0031854708     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701322     Document Type: Article

References (11)

1. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55-61.
2. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060.
3. Ehninger G, Schuler U, Renner U et al. Use of a water-soluble busulfan formulation - pharmacokinetic studies in a canine model. Blood 1995; 85: 3247-3249.
4. Schuler U, Schroer S, Kühnle A et al. Busulfan pharmacokinetics in BMT patients, is drug monitoring warranted? Bone Marrow Transplant 1994; 14: 759-765.
5. Blanz J, Rosenfeld C, Proksch B et al. Quantitaten of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis. J Chromatogr 1990; 532: 429-437.
6. Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
7. Hassan M, Oberg G, Bekassy AN et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28: 130-134.
8. Vassal G, Challine D, Koscielny S et al. Chronopharmacology of high-dose busulfan in children. Cancer Res 1993; 53: 1534-1537.
9. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230,
10. Schmiegelow K, Pulcynska M, Prognostic significance; of hepatotoxicity during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Br J Cancer 1990; 61: 767-772.
11. Shaw PJ, Scharping CE, Brian RJ et al Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84: 2357-2362.